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ABSTRACT
Objective: The aim of the study was to determine the importance of β-hCG level on day 4 following methotrexate (MTX) 
administration, and the difference between β-hCG levels assessed on day 0 and day 4 in predicting treatment success. 
Material and methods: A total of 68 women with tubal pregnancy, treated with a single dose of MTX, were selected for 
this retrospective study. 
Results: The success rate of single-dose MTX treatment in our clinic was 75% (51/68). Among 51 patients in whom MTX 
treatment was successful, 25 (36.8%) showed a decrease in β-hCG level of > 15% on days 0 and 4, and 44 (64.7%) showed 
a β-hCG level decrease of > 15% on days 4 and 7. For subjects with β-hCG decrease of > 15% on days 4 and 7, the standard 
error was 6.5%, and the area under the ROC curve was 81.7%, while the corresponding values for days 0 and 4 were 7.2% 
and 64%, respectively. 
Conclusions: A decrease of > 15 % in β-hCG levels between days 0 and 4 does not seem to be a better predictor for success 
of single-dose MTX treatment for ectopic pregnancy than between days 4 and 7. A statistically significant difference was 
observed only in β-hCG levels on day 7 in both, successful and unsuccessful single-dose MTX groups.
Key words: ectopic pregnancy, methotrexate, single dose, human chorionic gonadotropin, treatment success
Ginekologia Polska 2016; 87, 7: 484–487
Corresponding author:
Handan Çelik
University of Ondokuz Mayıs, School of Medicine, Department of Obstetrics and Gynecology, Samsun, Turkey
e-mail: drhandancelik@hotmail.com
INTRODUCTION
The incidence of ectopic pregnancy has been estimated 
at 2% [1]. Owing to the advances in transvaginal ultrasono- 
graphy, ectopic pregnancy can be diagnosed early and treated 
using medical rather than surgical methods. Methotrexate 
(MTX), an antifolate cytotoxic drug, was first used for treating 
a clinically stable ectopic pregnancy in 1982. Since then, it has 
been accepted as a reliable non-surgical method for treat-
ing ectopic pregnancies [2]. However, ectopic pregnancy 
can persist and progress, at a rate of 9–27%, even after MTX 
treatment. Therefore, patient selection for this treatment 
needs to be appropriate [3, 4]. MTX can be administered oral-
ly, systemically, or locally in the area of the ectopic pregnancy. 
However, systemic use is preferred over other modes of ad-
ministration. Systemic MTX treatment can involve multi-dose 
and single-dose protocols. Due to the fact that single-dose 
protocols are associated with fewer adverse effects and re-
quire a smaller amount of the drug, they are currently the 
most popular choice for treating ectopic pregnancies. In this 
protocol, MTX is administered intramuscularly (50 mg/m²), 
and β-human chorionic gonadotropin (hCG) level is moni-
tored on days 4 and 7 after administration. If the decrease in 
β-hCG concentration on days 4 and 7 exceeds 15%, the level 
is monitored by patient follow-up on a weekly basis. Due to 
unknown reasons, serum β-hCG level can increase until day 
4 after MTX administration [5, 6]. The β-hCG level on day 
7 is the most important criterion to determine whether the 
single-dose protocol was successful. Regardless, the success 
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of the therapy cannot be conclusively determined, and the 
decision about the administration of a repeat dose cannot 
be made until protocol completion.
OBJECTIVES
The purpose of the study was to investigate the impor-
tance of β-hCG level evaluation on day 4 following MTX 
administrations, and the differences between β-hCG levels 
assessed on days 0 and 4 for predicting treatment suc-
cess. We also aimed to analyze the success of MTX treatment 
in the early weeks of gestation. 
MATERIAL AND METHODS
Between 2008 and 2014, 234 patients were admitted 
to the Department of Gynecology and Obstetrics, On-
dokuz Mayıs University, due to tubal ectopic pregnancy. 
Of these patients, 166 received surgical and 68 received 
single-dose MTX treatment. The inclusion criteria for MTX 
treatment were as follows: (1) extrauterine gestational sac 
or absence of an intrauterine pregnancy despite β-hCG 
level of ≥ 1500 mIU/mL and a continuous increase in the 
levels; (2) absence of acute abdomen or hemoperitoneum; 
(3) absence of fetal heartbeat in the extrauterine sac; (4) 
β-hCG level of < 10000 mIU/mL and size of the extrauterine 
gestational sac of < 3.5 cm; (5) absence of hepatic dysfunc-
tion (high levels of liver function tests) or renal insufficiency 
(creatinine level of > 1.5 mg/dL); (6) absence of a known 
allergy to MTX; and (7) patient consent. 
Patients who met these criteria received single-dose 
MTX treatment. One day before MTX administration (day 
0), we performed liver and renal function tests, as well as 
blood count and β-hCG level measurements. The day of MTX 
administration (50 mg/m²) was considered day 1. There-
after, β-hCG levels were measured on days 4 and 7. If the 
decrease in β-hCG levels was > 15% between days 4 and 7, 
the patients were followed-up on a weekly basis until β-hCG 
levels could not be detected anymore. The second dose of 
MTX was administered if the patient condition was stable 
and a decrease in β-hCG levels was < 15%. Surgery was 
performed if patient condition was unstable (acute pelvic 
pain or indicating tubal rupture), or if the patient refused the 
second dose of MTX. The treatment was considered success-
ful if the condition resolved completely with a single dose 
of MTX and without any requirement for surgical treatment 
or the second dose. Serum β-hCG levels were determined 
using automated electrochemiluminescence immunoas-
says (Roche Hitachi Modular Analytics E170). Local Ethics 
Committee approved of the study.
Statistical analysis 
Number Cruncher Statistical System (NCSS) 2007 and 
Power Analysis and Sample Size (PASS) 2008 (Utah, USA) 
were used for statistical analyses. Student’s t test and the de-
finitive statistical methods (methods to calculate the mean, 
standard deviation, median, rate, and frequency) were used 
to compare normally distributed data. The U Mann-Whitney 
test was used to compare non-normally distributed data. 
Diagnostic screening tests (specificity, sensitivity, etc.) and 
receiver operating characteristic (ROC) curve analysis were 
performed to evaluate the changes in β-hCG levels during 
follow-up. The results were evaluated by determining a 95% 
confidence interval. The p-value of < 0.05 was considered 
as statistically significant.
RESULTS
A total of 68 patients (29.1%) received single-dose MTX 
treatment. Out of them, 51 (75%) responded to treatment. 
The remaining 17 patients (25%) did not respond to treat-
ment: multi-dose MTX treatment was administered to 7, 
while 10 received surgical treatment. 
Patients who did not respond to treatment formed 
a group in which single-dose MTX treatment was unsuc-
cessful. Mean patient age was 31 ± 5 years (mean ± SD) 
and 30 ± 5 years for those who underwent surgery and 
those who received a single dose of MTX, respectively. There 
were significant differences in serum β-hCG levels on day 
0 between these two groups. Median preoperative β-hCG 
level in patients who underwent surgery was 2800 mIU/mL 
(range: 116–59769 mIU/mL), and median β-hCG value on 
day 0 (i.e. before MTX treatment) in patients who received 
MTX was 1117 mIU/mL (range, 47–9319 mIU/mL) (p < 0.01). 
The success rate of single-dose MTX treatment in our 
clinic was 75% (51/68). Comparison of patients with and 
without successful response to single-dose MTX treatment 
(n = 51 and n = 17, respectively) revealed no statistically 
significant differences in age, gravidity, parity, and β-hCG 
levels on days 0 and 4. However, there were significant dif-
ferences in β-hCG levels on day 7 between the two groups 
(p < 0.05) (Table 1). 
In the group which received single-dose MTX treat-
ment, the β-hCG level decrease on days 4 and 0 was > 15% 
in 30 cases (44%), and was < 15% or increased in 38 (56%) 
cases. Among the 51 patients in whom the MTX treatment 
was successful, 25 (36.8%) showed a decrease in β-hCG level 
of > 15% on days 0 and 4. Sensitivity and specificity of the 
test were 49% and 70%, respectively. The positive predictive 
value was 83%, the negative predictive value was 31%, and 
the accuracy was 54% (Table 2).
When the decrease in β-hCG level between days 4 and 
7 was analyzed in all patients receiving MTX treatment, the 
level on day 7 was lower than on day 4, and this decrease 
was > 15% and < 15% in 50 (73%) and 18 patients (26%), 
respectively. Among the 51 patients in whom MTX treat-
ment was successful, 44 (64%) showed β-hCG level decrease 
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of > 15% on days 4 and 7. The sensitivity and specificity of the 
test were 86% and 64%, respectively. The positive predictive 
value was 88%, the negative predictive value was 61%, and 
the accuracy was 80% (Table 3). 
For the subjects in whom the β-hCG decrease was > 15% 
on days 4 and 7, the standard error was 6.5%, and the area 
under the ROC curve was 81%, and the corresponding values 
for days 0 and 4 were 7% and 64%, respectively. The 15% 
decrease between days 7 and 4 is an efficient predictor of 
the success of MTX treatment (Figure 1).
DISCUSSION
Early prediction of the outcomes of single-dose MTX 
treatment by measuring β-hCG between days 0 and 4 may 
Table 1. Comparison of the patients in whom single-dose methotrexate treatment was successful to those in whom the treatment was unsuccessful
Methotrexate treatment was 
successful (n = 51)
Methotrexate treatment was 
unsuccessful (n = 17) P
Mean ± SD Mean ± SD
Age
30.67 ± 5.24 29.94 ± 6.89 0.641
Median (Min-Max) Median (Min-Max) +p
Gravidity 2 (1–4) 1 (1–4) 0.042*
Parity 1 (0–3) 0 (0–3) 0.052
β-hCG (day 0) 1163 (range 47–9319) 1077 (range 191–6815) 0.772
β-hCG (day 4) 806 (range 12–5470) 1033 (range 252–5832) 0.099
β-hCG (day 7) 370 (range 3–4150) 1935 (range 191–16466) 0.004**
Student-t Test; + U Mann-Whitney Test; *p < 0.05; **p < 0.01
Table 2. Change in β-hCG on day 4 and day 0 after single dose methotrexate treatment
Single-dose methotrexate treatment
Successful Unsuccessful Total
n % n % n %
Change in β-hCG on day 
4 and day 0
> % 15 decrease 25 36.8 5 7.4 30 44.1
≤ % 15 decrease or increase 26 38.2 12 17.6 38 55.9
Total 51 75.0 17 25.0 68 100.0
Sensitivity 49
Specificity 70
Positive prediction value 83
Negative prediction value 31
Accuracy 54
Table 3. Change in β-hCG on day 7 and day 4 after single dose methotrexate treatment
Single-dose methotrexate treatment
Successful Unsuccessful Total
n % n % n %
Change in β-hCG on day 
7 and day 4
> % 15 decrease 44 64.7 6 8.8 50 73.5
≤ % 15 decrease 7 10.3 11 16.2 18 26.5
Total 51 75.0 17 25.9 68 100
Sensitivity 86
Specificity 64
Positive prediction value 88
Negative prediction value 61
Accuracy 80
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help to eliminate the necessity of a close 7-day follow-up of 
patients with predicted success. Also, it may help to determine 
the requirement of a second dose or more aggressive treat-
ment methods in patients showing unfavorable outcomes 
without delay. In this retrospective study, we aimed to evalu-
ate the decrease in the level of β-hCG between days 0 and 
4 (early β-hCG assessment), so as to use this measurement 
in predicting the success of single-dose MTX treatment. We 
found that a decrease of > 15% in β-hCG levels between days 
0 and 4 does not seem to be a better predictor for success of 
single-dose MTX treatment for ectopic pregnancy than be-
tween days 4 and 7. A statistically significant difference was 
observed only in β-hCG levels on day 7 in both, successful 
and unsuccessful single-dose MTX groups.
In our study, the sensitivity of the > 15% decrease in 
β-hCG levels between days 0 and 4 for predicting the success 
of single-dose MTX treatment was 49%, while the positive 
predictive value was 83%. With regard to the β-hCG level 
decrease of > 15% between days 7 and 4, the sensitivity 
of this predictor for treatment success was 86%, and the 
positive predictive value was 88%.
In the literature, the reported success rate of single-dose 
MTX treatment ranges between 65–96% [3, 7, 8]. The treat-
ment success rate in our study (75%) was similar to the suc-
cess rates reported in 2010 by Nguyen et al. (76%) [9], and 
by Skubiz et al. (77%) [10]. However, in the study by Nguyen 
et al., the predictive value of the β-hCG level decrease be-
tween days 0 and 4 for treatment success was very high. In 
their study, the success rate of single-dose MTX treatment 
in all patients in whom β-hCG levels decreased between 
days 0 and 4 (12 patients) was 100%, and they concluded 
that follow-up until day 7 may not be required in these pa-
tients [9]. Skubitz et al., stated that β-hCG levels decreased 
between days 0 and 4 in 29 out of 33 patients who were 
successfully treated with a single dose of MTX (88% suc-
cess rate), and this is a clinical indicator for predicting the 
success of single-dose MTX treatment, with the likelihood 
of 88% [10].
When the decrease between the values for days 0 and 
4 was taken into consideration, the probability of determin-
ing treatment success on the basis of β-hCG level decrease 
of > 15% was 83%. This result suggests that although the 
decrease between days 0 and 4 is important for predicting 
the success of single-dose MTX treatment, it is not a better 
predictor than β-hCG level calculated between days 4 and 7. 
Agostini et al., reported a probability of 97% for days 
0 and 4. However, the predictor used in their study was 
a β-hCG level decrease of > 20% between days 0 and 4, and 
the high probability of success achieved with this predictor 
can be attributed to the higher percentage of the decrease 
considered [11]. 
CONCLUSIONS
When β-hCG levels on days 0, 4, and 7 are considered as 
predictors of treatment success, significant differences are 
observed only between day 7 values in groups showing suc-
cessful and unsuccessful outcomes. Early β-hCG assessment 
on days 0 and 4 appears to be a poor predictor for success 
of single-dose MTX treatment in ectopic pregnancy.
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Figure 1. The area under the receiver operating characteristic curve
